Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 127

Results For "2022"

1420 News Found

Rahul Guha to join Thyrocare Technologies as MD & CEO
People | February 07, 2022

Rahul Guha to join Thyrocare Technologies as MD & CEO

Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice


Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
News | February 05, 2022

Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore

Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021


Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore
News | February 05, 2022

Sun Pharma Advanced Research Company Q3FY22 loss at Rs. 15.84 crore

Sun Pharma Advanced Research Company has reported standalone financial results for the period ended December 31, 2021


IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore
News | February 05, 2022

IOL Chemicals and Pharmaceuticals Q3FY22 PAT at Rs. 40.07 crore

IOL Chemicals and Pharmaceuticals has reported standalone financial results for the period ended December 31, 2021


Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
News | February 05, 2022

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021


Indian govt. places order for five crore doses of Corbevax
News | February 05, 2022

Indian govt. places order for five crore doses of Corbevax

Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius


Lupin Q3FY22 PAT at Rs 545.52 cr.
News | February 04, 2022

Lupin Q3FY22 PAT at Rs 545.52 cr.

Lupin has reported consolidated financial results for the period ended December 31, 2021


Pfizer Q3FY22 PAT at Rs 143.91 crore
News | February 04, 2022

Pfizer Q3FY22 PAT at Rs 143.91 crore

The company has reported standalone financial results for the period ended December 31, 2021.


Dr. Reddy’s impresses on sustainability and gender equality again
Sustainability | February 03, 2022

Dr. Reddy’s impresses on sustainability and gender equality again

Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row


Caplin Point Q3FY22 PAT at Rs 74.95 cr.
News | February 03, 2022

Caplin Point Q3FY22 PAT at Rs 74.95 cr.

Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.